Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31048110 | 1.00 | EGFR (0.36) | EGFRTRPV4ERN1CSF1RMAPT | |
| SCHEMBL1426162 | 0.85 | ALDH1A1 (0.33) | EGFRCSF1RMAPTGAA | |
| SCHEMBL13494621 | 0.85 | MAP3K14 (0.36) | EGFRTRPV4ERN1CSF1RMAPT | |
| SCHEMBL30916655 | 0.85 | MAP3K14 (0.36) | EGFRTRPV4ERN1CSF1RMAPT | |
| SCHEMBL26132427 | 0.84 | EGFR (0.39) | EGFRTRPV4ERN1CSF1R | |
| SCHEMBL26132369 | 0.84 | EGFR (0.37) | EGFRCSF1RNPC1 | |
| SCHEMBL5899654 | 0.84 | ALDH1A1 (0.35) | EGFR | |
| SCHEMBL30994304 | 0.83 | EGFR (0.31) | EGFR | |
| SCHEMBL1506020 | 0.83 | TSHR (0.33) | EGFRMAPT | |
| SCHEMBL30413175 | 0.80 | HPGD (0.42) | EGFRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-08-22 | — | — | US | disclosed |
| CN-118119626-A | Fused bicyclic heteroaryl compounds useful as NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022089449-A1 | PREPARATION OF SPECIFIC HEAT SHOCK PROTEIN 90α SUBTYPE INHIBITOR AND USE THEREOF | 山东大学 | 2022-05-05 | — | — | WO | disclosed |
| WO-2011151651-A1 | BENZODIAZEPINE COMPOUNDS USEFUL FOR THE TREATMENT OF HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151652-A1 | BENZODIAZEPINE COMPOUNDS USEFUL FOR THE TREATMENT OF HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151652-A1 | BENZODIAZEPINE COMPOUNDS USEFUL FOR THE TREATMENT OF HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151651-A1 | BENZODIAZEPINE COMPOUNDS USEFUL FOR THE TREATMENT OF HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011027156-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011027156-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| US-20110059043-A1 | CHEMICAL COMPOUNDS | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059043-A1 | CHEMICAL COMPOUNDS | CYP2E1, CNR1, CYP3A5 | EGFR 1029/4885TRPV4 1387/4885ERN1 1077/4885 |
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | EGFR 4573/4885TRPV4 2739/4885ERN1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.